Journal of Stem Cell Research & Therapy

Engineered erythrocytes as an anti-tumor therapy through induction of apoptosis or immune-checkpoint inhibition

6^th International Conference and Exhibition on Cell and Gene Therapy

March 27-28, 2017 Madrid, Spain

Robert J Deans

Rubius Therapeutics, USA

Posters & Accepted Abstracts: J Stem Cell Res Ther

Abstract:

Rubius Therapeutics has built a platform for producing allogeneic Red Cell Therapeutics (RCTs), genetically modified red blood cells expanded ex vivo. Using lentiviral gene delivery, RCTs are able to harbor active intracellular as well as extracellular proteins, ranging from enzymes and cell targeting moieties to agonists and antibodies. RCTs represent a potentially transformational oncology platform, enabling multiple distinct modalities including tumor starvation, enhanced apoptotic signaling and immune checkpoint inhibition, among others. Further studies are underway to evaluate the ability of these and other RCTs to access and kill tumor cells in vitro and in vivo. These data support the development of RCTs as a novel class of therapeutic, enabling multiple modalities and mechanisms applicable to oncology and other indications.

Biography :

Email: rdeans@athersys.com